Mirum Pharmaceuticals Inc... (MIRM)
| Bid | 45.77 |
| Market Cap | 2.3B |
| Revenue (ttm) | 341.6M |
| Net Income (ttm) | -89.17M |
| EPS (ttm) | -1.85 |
| PE Ratio (ttm) | -25.39 |
| Forward PE | -92.94 |
| Analyst | Buy |
| Ask | 60 |
| Volume | 164,153 |
| Avg. Volume (20D) | 516,838 |
| Open | 47.84 |
| Previous Close | 47.02 |
| Day's Range | 46.45 - 47.99 |
| 52-Week Range | 23.14 - 54.23 |
| Beta | 1.04 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...
Analyst Forecast
According to 11 analyst ratings, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 40.52% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call TranscriptMirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Rela...
1 month ago · businesswire.com
Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)FOSTER CITY, Calif.--(BUSINESS WIRE)-- #ctx--Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX).
